Plasma osteopontin levels in multiple sclerosis

Journal of Neuroimmunology

Volumn 158, Issue 1-2, 2005, Pages 231-239

  Comabella, Manuel ^a   Pericot, Imma ^a   Goertsches, Robert ^a   Nos, Carlos ^a   Castillo, Mireia ^a   Blas Navarro, José ^b   Río, Jordi ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cytokine; Multiple sclerosis; Osteopontin

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; OSTEOPONTIN; RECOMBINANT BETA INTERFERON;

ACUTE DISEASE; ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; CONFIDENCE INTERVALS; DEMOGRAPHY; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOPONTIN; SIALOGLYCOPROTEINS;

EID: 10344246601     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.09.004     Document Type: Article

References (51)

1. S. Ashkar, G.F. Weber, V. Panoutsakopoulou, M.E. Sanchirico, M. Jansson, S. Zawaideh, S.R. Rittling, D.T. Denhardt, M.J. Glimcher, and H. Cantor Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity Science 287 2000 860 864
2. K.E. Balashov, D.R. Smith, S.J. Khoury, D.A. Hafler, and H.L. Weiner Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+T cells via CD40 ligand Proc. Natl. Acad. Sci. U. S. A. 94 1997 599 603
3. T. Blom, A. Franzen, D. Heinegard, and R. Holmdahl Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease" Science 299 2003 1845
4. S. Caillier, L.F. Barcellos, S.E. Baranzini, A. Swerdlin, R.R. Lincoln, L. Steinman, E. Martin, J.L. Haines, M. Pericak-Vance, S.L. Hauser, J.R. Oksenberg Multiple Sclerosis Genetics Group Osteopontin polymorphisms and disease course in multiple sclerosis Genes Immun. 4 2003 312 315
5. B. Cannella, and C.S. Raine The adhesion molecule and cytokine profile of multiple sclerosis lesions Ann. Neurol. 37 1995 424 435
6. D. Chabas, S.E. Baranzini, D. Mitchell, C.C. Bernard, S.R. Rittling, D.T. Denhardt, R.A. Sobel, C. Lock, M. Karpuj, R. Pedotti, R. Heller, J.R. Oksenberg, and L. Steinman The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease Science 294 2001 1731 1735
7. M. Comabella, K. Balashov, S. Issazadeh, D. Smith, H.L. Weiner, and S.J. Khoury Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy J. Clin. Invest. 102 1998 671 678
8. D.T. Denhardt, M. Noda, A.W. O'Regan, D. Pavlin, and J.S. Berman Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival J. Clin. Invest. 107 2001 1055 1061
9. I. Duran, E.M. Martinez-Caceres, J. Rio, N. Barbera, M.E. Marzo, and X. Montalban Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules Brain 122 1999 2297 2307
10. J.A. Ellison, J.J. Velier, P. Spera, Z.L. Jonak, X. Wang, F.C. Barone, and G.Z. Feuerstein Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke Stroke 29 1998 1698 1707
11. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis Lancet 352 1998 1491 1497
12. P. Ferrante, M.L. Fusi, M. Saresella, D. Caputo, M. Biasin, D. Trabattoni, A. Salvaggio, E. Clerici, J.E. de Vries, G. Aversa, C.L. Cazzullo, and M. Clerici Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis J. Immunol. 160 1998 1514 1521
13. C.M. Giachelli, D. Lombardi, R.J. Johnson, C.E. Murry, and M. Almeida Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo Am. J. Pathol. 152 1998 353 358
14. A.P. Gilmore, A.D. Metcalfe, L.H. Romer, and C.H. Streuli Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization J. Cell Biol. 149 2000 431 446
15. G. Giovannoni, M. Lai, J. Thorpe, D. Kidd, V. Chamoun, A.J. Thompson, D.H. Miller, M. Feldmann, and E.J. Thompson Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging Neurology 48 1997 1557 1565
16. P.A. Hill, A. Tumber, and M.C. Meikle Multiple extracellular signals promote osteoblast survival and apoptosis Endocrinology 138 1997 3849 3858
17. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, A.M. Salazar, J.S. Fischer, D.E. Goodkin, C.V. Granger, J.H. Simon, J.J. Alam, D.M. Bartoszak, D.N. Bourdette, J. Braiman, C.M. Brownscheidle, M.E. Coats, S.L. Cohan, D.S. Dougherty, R.P. Kinkel, M.K. Mass, F.E. Munschauer III, R.L. Priore, P.M. Pullicino, B.J. Scherokman, and R.H. Whitham Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann. Neurol. 39 1996 285 294
18. M. Jansson, V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice J. Immunol. 168 2002 2096 2099
19. X.J. Jiang, T. Feng, L.S. Chang, X.T. Kong, G. Wang, Z.W. Zhang, and Y.L. Guo Expression of osteopontin mRNA in normal and stone-forming rat kidney Urol. Res. 26 1998 389 394
20. M. Kerschensteiner, C. Stadelmann, G. Dechant, H. Wekerle, and R. Hohlfeld Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases Ann. Neurol. 53 2003 292 304
21. Y. Koguchi, K. Kawakami, S. Kon, T. Segawa, M. Maeda, T. Uede, and A. Saito Penicillium marneffei causes osteopontin-mediated production of interleukin-12 by peripheral blood mononuclear cells Infect. Immun. 70 2002 1042 1048
22. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
23. Y.H. Lin, C.J. Huang, J.R. Chao, S.T. Chen, S.F. Lee, J.J. Yen, and H.F. Yang-Yen Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor Mol. Cell. Biol. 20 2000 2734 2742
24. F.D. Lublin, and S.C. Reingold Defining the clinical course of multiple sclerosis: results of an international survey Neurology 46 1996 907 911
25. H. Makino, H. Sugiyama, and N. Kashihara Apoptosis and extracellular matrix-cell interactions in kidney disease Kidney Inter., Suppl. 77 2000 S67 S75
26. U.M. Malyankar, M. Scatena, K.L. Suchland, T.J. Yun, E.A. Clark, and C.M. Giachelli Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells J. Biol. Chem. 275 2000 20959 20962
27. R. Martin, H.F. McFarland, and D.E. McFarlin Immunological aspects of demyelinating diseases Annu. Rev. Immunol. 10 1992 153 187
28. G.V. McDonnell, S.A. McMillan, J.P. Douglas, A.G. Droogan, and S.A. Hawkins Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease J. Neurol. 246 1999 87 92
29. J.E. Merrill, L.J. Ignarro, M.P. Sherman, J. Melinek, and T.E. Lane Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide J. Immunol. 151 1993 2132 2141
30. B. Mitrovic, L.J. Ignarro, S. Montestruque, A. Smoll, and J.E. Merrill Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro Neuroscience 61 1994 575 585
31. C.E. Murry, C.M. Giachelli, S.M. Schwartz, and R. Vracko Macrophages express osteopontin during repair of myocardial necrosis Am. J. Pathol. 145 1994 1450 1462
32. V. Navikas, and H. Link Review: cytokines and the pathogenesis of multiple sclerosis J. Neurosci. Res. 45 1996 322 333
33. V. Navikas, B. He, J. Link, M. Haglund, M. Soderstrom, S. Fredrikson, A. Ljungdahl, J. Hojeberg, J. Qiao, T. Olsson, and H. Link Augmented expression of tumor necrosis and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis Brain 119 1996 213 223
34. F. Nicoletti, F. Patti, C. Cocuzza, P. Zaccone, A. Nicoletti, R. Di Marco, and A. Reggio Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis J. Neuroimmunol. 70 1996 87 90
35. M. Niino, S. Kikuchi, T. Fukazawa, I. Yabe, and K. Tashiro Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients J. Neuroimmunol. 136 2003 125 129
36. A. Oldberg, A. Franzen, and D. Heinegard Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence Proc. Natl. Acad. Sci. U. S. A. 83 1986 8819 8823
37. V. Ophascharoensuk, C.M. Giachelli, K. Gordon, J. Hughes, R. Pichler, P. Brown, L. Liaw, R. Schmidt, S.J. Shankland, C.E. Alpers, W.G. Couser, and R.J. Johnson Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis Kidney Int. 56 1999 571 580
38. A. O'Regan, and J.S. Berman Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation Int. J. Exp. Pathol. 81 2000 373 390
39. A.W. O'Regan, G.J. Nau, G.L. Chupp, and J.S. Berman Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks Immunol. Today 21 2000 475 478
40. J. Palace Clinical and laboratory characteristics of secondary progressive MS J. Neurol. Sci. 206 2003 131 134
41. J. Philippe, J. Debruyne, G. Leroux-Roels, A. Willems, and J. Dereuck In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis Clin. Neurol. Neurosurg. 98 1996 286 290
42. T. Revesz, D. Kidd, A.J. Thompson, R.O. Barnard, and W.I. McDonald A comparison of the pathology of primary and secondary progressive multiple sclerosis Brain 117 1994 759 765
43. P. Rieckmann, M. Albrecht, B. Kitze, T. Weber, H. Tumani, A. Broocks, W. Luer, A. Helwig, and S. Poser Tumor necrosis factor-messenger RNA expression in patients with multiple sclerosis is associated with disease activity Ann. Neurol. 37 1995 82 88
44. S.R. Rittling, and D.T. Denhardt Osteopontin function in pathology: lessons from osteopontin-deficient mice Exp. Nephrol. 7 1999 103 113
45. C. Stadelmann, M. Kerschensteiner, T. Misgeld, W. Bruck, R. Hohlfeld, and H. Lassmann BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125 2002 75 85
46. A.J. Thompson, C.H. Polman, D.H. Miller, W.I. McDonald, B. Brochet, M. Filippi, X. Montalban, and J. De Sa Primary progressive multiple sclerosis Brain 120 1997 1085 1096
47. A.H. Van Boxel-Dezaire, S.C. Hoff, B.W. van Oosten, C.L. Verweij, A.M. Drager, H.J. Ader, J.C. van Houwelingen, F. Barkhof, C.H. Polman, and L. Nagelkerken Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis Ann. Neurol. 45 1999 695 703
48. A.H. Van Boxel-Dezaire, M. Smits, S.C. van Trigt-Hoff, J. Killestein, J.C. van Houwelingen, C.H. Polman, and L. Nagelkerken Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis J. Neuroimmunol. 120 2001 152 160
49. M.H. Vogt, L. Lopatinskaya, M. Smits, C.H. Polman, and L. Nagelkerken Elevated osteopontin levels in active relapsing-remitting multiple sclerosis Ann. Neurol. 53 2003 819 822
50. X. Wang, C. Louden, T.L. Yue, J.A. Ellison, F.C. Barone, H.A. Solleveld, and G.Z. Feuerstein Delayed expression of osteopontin after focal stroke in the rat J. Neurosci. 18 1998 2075 2083
51. B.G. Weinshenker, B. Bass, G.P. Rice, J. Noseworthy, W. Carriere, J. Baskerville, and G.C. Ebers The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability Brain 112 1989 133 146